Clinical Trials for Lymphoblastic Lymphoma: 3 Recruiting

Every trial in this listing is drawn from ClinicalTrials.gov, the federal registry of clinical research operated by the U.S. National Library of Medicine. Each entry on ClinicalTrials.gov is filed by the study sponsor and includes a unique NCT identifier, study design, eligibility criteria, intervention details, sponsor information, sites, and status. TrialFinder reorganizes that public registry data so it is browsable by condition, sponsor, phase, and geography.

Lymphoblastic Lymphoma is a relatively narrow research area in this dataset, with 3 trials out of the 7,755 indexed (about 0.04%). Smaller research footprints are common for rare conditions and for areas where standard-of-care therapy is already well established. Eligible patients may need to travel to participating sites. The most common intervention being tested in Lymphoblastic Lymphoma trials is LP-118 (drug-class), followed by Ponatinib, Vincristine. Intervention type matters because it shapes what participation looks like — drug studies typically involve scheduled dosing and bloodwork, device trials involve a procedure or implant, and behavioral studies may only require visits and surveys.

Clinical trials are how new therapies, devices, and procedures get tested before the U.S. Food and Drug Administration decides whether to approve them for general use. Federal law requires most U.S.-based interventional trials to be registered on ClinicalTrials.gov, and many international trials are listed voluntarily. That makes the registry the most comprehensive single window into active medical research for Lymphoblastic Lymphoma and other conditions.

Lymphoblastic Lymphoma research is led primarily by academic medical centers — roughly 67% of listed sponsors are universities, teaching hospitals, or research institutes. Industry funds about 33% of trials, with the remainder backed by government science agencies. That mix often signals investigator-initiated research and earlier-stage science rather than late-stage commercial development.

The sponsor matters because it shapes how a trial is designed and run. Industry-sponsored studies are usually tightly protocoled and tied to a regulatory submission. Academic studies often investigate questions a commercial sponsor would not, including comparisons between existing therapies, mechanism-of-disease research, and approaches for patient subgroups too small to be commercially attractive. Government-funded research, including programs run by the National Institutes of Health, frequently focuses on public-health priorities, prevention, and long-term outcomes.

Combined Phase 1/2 protocols start with safety and dose-finding, then expand seamlessly into efficacy testing without re-enrolling. They are common in oncology and rare-disease research where eligible patients are scarce.

Almost every listed Lymphoblastic Lymphoma trial in this dataset is currently recruiting — 3 of 3 studies are actively seeking participants. That high active rate reflects the dataset's focus on enrollment-open studies and means there are real, near-term opportunities for eligible patients to take part.

The development phase tells you what question a trial is asking. Early-phase studies (Phase 1 and Early Phase 1) are about safety and dosing. Phase 2 studies look for an efficacy signal. Phase 3 studies generate the evidence regulators use to decide whether a therapy is approved for general clinical use. Phase 4 studies happen after approval and look at long-term outcomes in real-world settings. Trials labeled "Not Applicable" are typically observational or device studies that do not fit the drug-trial framework.

Lymphoblastic Lymphoma is a relatively narrow research area in this dataset, with 3 trials out of the 7,755 indexed (about 0.04%). Smaller research footprints are common for rare conditions and for areas where standard-of-care therapy is already well established. Eligible patients may need to travel to participating sites.

Across the full TrialFinder dataset of 7,755 indexed studies and 2,541 distinct conditions, the most heavily researched areas tend to cluster around oncology, metabolic disease, and neurology — areas with both large patient populations and active commercial investment. Rare diseases and pediatric conditions usually have smaller absolute trial counts but a higher share of academically and federally funded studies. The Lymphoblastic Lymphoma mix above reflects where this condition currently sits on that spectrum.

Because most Lymphoblastic Lymphoma trials in this dataset are early-phase, eligibility tends to be tightly defined — small participant counts, narrow age windows, and strict requirements around prior treatments and overall health. Patients interested in early-phase research should expect a careful screening process and should discuss with their physician whether the safety profile fits their situation.

Practical participation considerations include travel to a study site (most trials require in-person visits at a hospital or research center), time commitment (visits often run hours each, with some trials lasting years), and out-of-pocket costs. Trial sponsors typically cover the investigational therapy and study-required tests, but standard-of-care costs may still be billed to the participant or their insurer. A study coordinator can clarify which costs are covered before consent.

Patients and caregivers researching Lymphoblastic Lymphoma trials should treat any listing as a starting point for a conversation with their physician. The treating clinician knows the patient's full medical history, current medications, and overall treatment plan, and is best positioned to flag interactions and risks that a registry summary cannot capture. A second medical opinion from a specialist treating Lymphoblastic Lymphoma is often valuable before consenting to participate.